Botanix News Hub
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Investor Conference Call
/in Featured, Latest News, News /by Haley ChartresBotanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, and Executive Director, Matt Callahan, hosted an investor conference call on Friday 7 May 2021.
You may listen to the audio file here:
Ticker News Interview
/in Featured, Latest News, News, Videos /by Haley ChartresBotanix Pharmaceutical’s (ASX:BOT) Executive Director, Matt Callahan, spoke with the Ticker News team yesterday to detail the next phase of our BTX 1801 antimicrobial program, which will target nasal decolonisation of Staph aureus in haemodialysis patients.
Investor Presentation + Conference Call
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix Pharmaceuticals has today released an updated investor presentation and registration details for a conference call with our investors and supporters.
participants can pre-submit questions to be answered at the end of the call, when registering through the link below.
See the updated investor presentation here.
Conference call details:
Date: Friday, 7 May 2021
Time: 11:00am AEST
Registration details:
Participants are encouraged to pre-register for the conference call. Upon registration, participants will receive a unique pin granting fast-track access to the conference call and the opportunity to submit questions to our team.
Register now.
BTX 1801 Clinical Development Update
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix Pharmaceuticals has today released a comprehensive update and presentation on imminent plans for the BTX 1801 antimicrobial platform program.
The next phase of development for BTX 1801 will focus on targeting the nasal decolonisation of Staph aureus in haemodialysis patients, which represents a significant market opportunity to prevent bloodstream infections in these patients.
Dialysis largely replicates the functions of the kidneys in patients with chronic kidney failure, with dialysis taking over the key functions of the kidneys (including filtering and removing waste materials from the body). Haemodialysis patients undergoing ongoing dialysis regularly (e.g. three to five times per week), are at a high risk of bloodstream infections, due to their treatment requiring frequent use of catheters which in the first year are routinely central lines with direct access to the heart.
Our team is energised by the opportunity to develop a novel approach for removing sources of bacteria to prevent bloodstream infections in haemodialysis patients – which is desperately needed. Our prior work to examine the unique bactericidal mechanism of action of synthetic cannabidiol provides great confidence for this program too.
Read today’s ASX release and presentation here.
New AMR publication
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix Pharmaceutical’s ground-breaking research on the antimicrobial potential of cannabidiol (CBD) has been published by a leading South American academic group in BioRxiv.
The BioRxiv article confirms our discovery that synthetic CBD can also kill a select group of Gram-negative bacteria, including the bacteria responsible for the sexually transmitted disease gonorrhoea and the increasingly challenging Clostridioides difficile (C.Diff) infections.
The BioRxiv Paper follows the publication of our research in Nature Research’s peer-reviewed journal Communications Biology in January 2021, which is continuing to drive conversation around the potential of CBD to address antimicrobial resistance, globally.
Read today’s ASX release.
Freethink Feature Article
/in Featured, Latest News, News /by Haley ChartresSenior writer for Freethink, B.David Zarley, has published a feature article titled ‘Can CBD be the Next Superbug Slayer?’
It examines the importance Botanix’s research into the antimicrobial potential of cannabidiol and includes comments from Dr Mark Blaskovich, Director of UQ’s IMB Centre for Superbug Solutions and collaborator on our BTX 1801 antimicrobial research.
Read the Freethink article here.